Gabrail Cancer & Research Center
Skip to content
  • For Patients
    • New Patients
      • Request An Appointment
      • Referrals
    • What to expect?
      • Symptom Management
    • Patient Testimonials
    • Satisfaction Survey
  • Our Services
    • Clinical Trials
      • Clinical Research Trials (CRT)
    • Infusion Therapy
    • Instant Imaging
    • On Site Lab Services
    • The Liberty Pharmacy
    • Family Cancer Registry
    • Community Outreach
  • Clinical Trials
    • Clinical Trials at GCC
    • About Clinical Trials
      • Clinical Trial Phases
    • For Sponsors
      • Sponsor Testimonials
    • Approved Oncology Drugs
  • About Us
    • Physicians
    • Our Staff
    • Mission Statement
    • Location
    • Careers
  • Media
    • Podcasts
      • The Cancer Gene
      • Good Medicine Is Cheaper Medicine
    • Radio
    • TV
    • Articles
August 15, 2016 gabrailcancercenter

Pancreatic Cancer

The Gabrail Cancer Center currently has many Clinical Trial opportunities . For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or email CSmith@GabrailCancerCenter.com.

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Fluorouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine

A Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Ampligen® Compared to Control Group / No Treatment Following FOLFIRINOX in Subjects with Locally Advanced Pancreatic Adenocarcinoma

A Phase 1b/2 Randomized Study of AVB-S6-500 plus Nab-paclitaxel and Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Return to Clinical Trials at GCC

Subscribe to Podcast

4875 Higbee Ave NW Canton, OH 44718
cantondesk@gabrailcancercenter.com
330-492-3345
  • Facebook link
  • Instagram link
Zerif Lite developed by ThemeIsle
This website uses cookies to improve your experience. We'll assume you accept this policy as long as you are using this websiteAcceptView Policy